CRISM Therapeutics Corporation (LON:CRTX)
10.75p+2.38%
Spriggl Score: Weak— see the number + sub-scores with a free Spriggl account
Last 30 trading days
Spriggl AI Verdict
“Binary biotech — phase 2 brain cancer trial is the only route to value.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs. Its lead product is ChemoSeed, an implantable biodegradable drug delivery technology for the del…
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- £6.0M
Recent dividends
- 1 Jun 20232.88p
Get the full Spriggl analysis — free
Sign up for a free Spriggl account to unlock the full Spriggl Score breakdown, screener, watchlist, and AI investment analysis on CRISM Therapeutics Corporation and 1,600+ UK and US stocks.
Start free